

OFFICE OF FISCAL ANALYSIS

Legislative Office Building, Room 5200
Hartford, CT 06106 ◊ (860) 240-0200
<http://www.cga.ct.gov/ofa>

SB-188

AN ACT REQUIRING BRAND NAME PRESCRIPTION DRUG MANUFACTURERS TO PROVIDE SAMPLES OF BRAND NAME DRUGS TO GENERIC PRESCRIPTION DRUG MANUFACTURERS.

OFA Fiscal Note

State Impact:

Agency Affected	Fund-Effect	FY 23 \$	FY 24 \$
Consumer Protection, Dept.	GF - Potential Cost	80,071	77,971
State Comptroller - Fringe Benefits ¹	GF - Potential Cost	31,602	31,602

Note: GF=General Fund

Municipal Impact: None

Explanation

The bill creates a new Connecticut Unfair Trade Practice violation and to the extent this results in numerous new investigations there is a potential total cost to the state of \$111,673 in FY 23 and \$109,573 FY 24 for the Department of Consumer Protection to hire one attorney.

The Out Years

The annualized ongoing fiscal impact identified above would continue into the future subject to inflation.

¹The fringe benefit costs for most state employees are budgeted centrally in accounts administered by the Comptroller. The estimated active employee fringe benefit cost associated with most personnel changes is 40.53% of payroll in FY 23.

Primary Analyst: ME
Contributing Analyst(s):
Reviewer: PR

3/29/22